| Name | Title | Contact Details |
|---|
AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Reflex Photonics Inc. is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Molecular Therapeutics, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.